Anti-cancer Drugs

Anti-cancer Drugs

抗癌药

  • 4区 中科院分区
  • Q3 JCR分区

期刊简介

《Anti-cancer Drugs》是由Lippincott Williams and Wilkins Ltd.出版社于1990年创办的英文国际期刊(ISSN: 0959-4973,E-ISSN: 1473-5741),该期刊长期致力于肿瘤学领域的创新研究,主要研究方向为医学-药学。作为SCIE收录期刊(JCR分区 Q3,中科院 4区),本刊采用OA未开放获取模式(OA占比0.0343...%),以发表肿瘤学领域等方向的原创性研究为核心(研究类文章占比86.62%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在142篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Anti-cancer Drugs审稿周期约为 偏慢,4-8周 。该刊近年未被列入国际预警名单,年发文量约142篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 142 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ONCOLOGY 肿瘤学 PHARMACOLOGY & PHARMACY 药学
4区 4区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
ONCOLOGY 肿瘤学 PHARMACOLOGY & PHARMACY 药学
4区 4区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 241 / 322

25.3%

学科:PHARMACOLOGY & PHARMACY SCIE Q3 240 / 354

32.3%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q3 169 / 322

47.67%

学科:PHARMACOLOGY & PHARMACY SCIE Q3 190 / 354

46.47%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:3.8 SJR:0.476 SNIP:0.36
学科类别 分区 排名 百分位
大类:Medicine 小类:Pharmacology (medical) Q2 129 / 272

52%

大类:Medicine 小类:Oncology Q3 218 / 404

46%

大类:Medicine 小类:Pharmacology Q3 181 / 313

42%

大类:Medicine 小类:Cancer Research Q3 161 / 230

30%

期刊发文

  • MiR-302c-5p affects the stemness and cisplatin resistance of nasopharyngeal carcinoma cells by regulating HSP90AA1

    Author: Zhou, Xiangqi; Zheng, Le; Zeng, Chunya; Wu, Yangjie; Tang, Xiyang; Zhu, Yuan; Tang, Sanyuan

    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 135-143. DOI: 10.1097/CAD.0000000000001392

  • Purvalanol A induces apoptosis and reverses cisplatin resistance in ovarian cancer

    Author: Zhang, Xiaoyi; Hong, Shasha; Yang, Jiang; Liu, Jingchun; Wang, Ying; Peng, Jiaxin; Wang, Haoyu; Hong, Li

    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 29-43. DOI: 10.1097/CAD.0000000000001339

  • Hsa_circ_0007380 silencing restrains the growth and enhances radiosensitivity in esophagus cancer by miR-644a/Spindlin 1 axis

    Author: Yu, Weihui; Ning, Ke; Xiao, Jincheng; Bai, Qiwen; Guo, Chenyang

    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 166-177. DOI: 10.1097/CAD.0000000000001375

  • Circ-ABCC4 contributes to prostate cancer progression and radioresistance by mediating miR-1253/SOX4 cascade

    Author: Yu, Tao; Du, Hong; Sun, Changhai

    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 155-165. DOI: 10.1097/CAD.0000000000001361

  • Circ_0058608 contributes to the progression and taxol resistance of non-small cell lung cancer by sponging miR-1299 to upregulate GBP1

    Author: Xuan, Xianglan; Wang, Zhiguang; Wang, Yayan

    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 103-114. DOI: 10.1097/CAD.0000000000001346

  • LOC554202 contributes to chordoma progression by sponging miR-377-3p and up-regulating SMAD3

    Author: Xu, Guang; Liu, Jingnan; He, Jun; He, Haibo; Su, Xiaotao; Gui, Qianhuan

    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 15-28. DOI: 10.1097/CAD.0000000000001327

  • GATA3 positively regulates PAR1 to facilitate in vitro disease progression and decrease cisplatin sensitivity in neuroblastoma via inhibiting the hippo pathway

    Author: Wang, Jing; Dai, Wang; Zhang, Ming

    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 57-72. DOI: 10.1097/CAD.0000000000001341

  • Herpesvirus entry mediator regulates the transduction of Tregs via STAT5/Foxp3 signaling pathway in ovarian cancer cells

    Author: Shan, Ying; Zhang, Beibei; Chen, Li; Zhang, Hu; Jiang, Cui; You, Qinghua; Li, Yanyi; Han, Hongyu; Zhu, Jianlong

    Journal: ANTI-CANCER DRUGS. 2023; Vol. 34, Issue 1, pp. 73-80. DOI: 10.1097/CAD.0000000000001336